Goldman Sachs Group Inc. Takes $673,000 Position in Monopar Therapeutics Inc. $MNPR

Key Points

• Goldman Sachs Group Inc. acquired a new position in Monopar Therapeutics Inc. worth approximately $673,000, representing about 0.30% of the company’s stock.
• Monopar's stock recently experienced a 7.9% increase, with a current market capitalization of $450.66 million and a P/E ratio of -21.93.
• Analysts have a consensus rating of "Buy" for Monopar Therapeutics, with target prices ranging from $60.00 to $106.00.

Goldman Sachs Group Inc. bought a new position in Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 18,480 shares of the company's stock, valued at approximately $673,000. Goldman Sachs Group Inc. owned approximately 0.30% of Monopar Therapeutics as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new stake in Monopar Therapeutics in the first quarter worth approximately $377,000. OMERS ADMINISTRATION Corp bought a new stake in Monopar Therapeutics in the first quarter worth approximately $328,000. Affinity Asset Advisors LLC bought a new stake in Monopar Therapeutics in the first quarter worth approximately $2,257,000. AlphaQuest LLC bought a new stake in Monopar Therapeutics in the first quarter worth approximately $44,000. Finally, Gerber LLC bought a new stake in Monopar Therapeutics in the first quarter worth approximately $204,000. 1.83% of the stock is owned by institutional investors.

Monopar Therapeutics Trading Up 7.9%

NASDAQ MNPR opened at $73.04 on Thursday. The company has a fifty day simple moving average of $43.25 and a 200 day simple moving average of $38.70. The company has a market cap of $450.66 million, a P/E ratio of -21.93 and a beta of 1.20. Monopar Therapeutics Inc. has a 1 year low of $4.12 and a 1 year high of $74.00.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.12. Equities research analysts forecast that Monopar Therapeutics Inc. will post -1.65 EPS for the current fiscal year.

Insider Buying and Selling at Monopar Therapeutics

In other Monopar Therapeutics news, Director Christopher M. Starr sold 16,800 shares of the stock in a transaction on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the sale, the director directly owned 5,173 shares of the company's stock, valued at $206,920. This represents a 76.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Chandler Robinson sold 16,800 shares of the stock in a transaction on Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the sale, the chief executive officer directly owned 73,472 shares of the company's stock, valued at approximately $2,938,880. This trade represents a 18.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 42,504 shares of company stock valued at $1,700,160 in the last ninety days. Company insiders own 20.50% of the company's stock.

Analyst Ratings Changes

MNPR has been the subject of several recent research reports. Lake Street Capital initiated coverage on shares of Monopar Therapeutics in a research report on Tuesday. They issued a "buy" rating and a $106.00 target price for the company. Chardan Capital reissued a "buy" rating and issued a $60.00 target price on shares of Monopar Therapeutics in a research report on Tuesday, September 16th. Raymond James Financial started coverage on shares of Monopar Therapeutics in a research report on Tuesday, September 2nd. They issued a "strong-buy" rating and a $80.00 target price for the company. HC Wainwright started coverage on shares of Monopar Therapeutics in a report on Tuesday, August 26th. They set a "buy" rating and a $70.00 price objective for the company. Finally, Oppenheimer started coverage on shares of Monopar Therapeutics in a report on Wednesday, September 3rd. They set an "outperform" rating and a $77.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, Monopar Therapeutics has a consensus rating of "Buy" and a consensus target price of $75.56.

Monopar Therapeutics Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.